Neuroprotective therapy in advanced primary open-angle glaucoma
Dorofeev DA, Kozlova IV, Vereshchagina AI · 2025 · Vestnik oftalmologii. 2025;141:75-80.
Study findings
The treated cohort had smaller annual declines in visual-field mean deviation and retinal nerve-fiber thickness than untreated controls. Intraocular pressure was controlled in both groups.
- Population and setting
- 56 patients (98 eyes), advanced glaucoma; prospective two-center cohort, 2022–2024
- Evidence type
- Uncontrolled human report
- Preparation
- Retinalamin tissue-derived preparation
- Source language
- English abstract; original language varies
- Title source
- Title as recorded in the linked source or index. A separate original-language title has not been transcribed unless shown above.
Study limitations
- Nonrandomized cohort; treatment selection and other confounding may explain part of the difference.
- The abstract does not establish a blinded comparison or a causal reduction in vision loss.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Source access and review scope
PubMed-indexed abstract and bibliographic metadata checked via Europe PMC; full methods not appraised.
Recorded source-check date: 2026-10-07. This date does not imply a completed systematic review.
Citation and original source
Original source: Dorofeev DA, Kozlova IV, Vereshchagina AI. Neuroprotective therapy in advanced primary open-angle glaucoma Vestnik oftalmologii. 2025;141:75-80. 2025.
Molekul research summary: https://molekul.io/research/lineage-41432508. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry